Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cochlear.
RELATED STOCKHEAD STORIES
Experts
ScoPo’s health powerplays: What to look for this earnings season
Experts
ScoPo’s health powerplays: ‘We’re buying any pullbacks’
Experts
Scopo’s powerplays: Investors love a result, until they don’t
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Health & Biotech
We’re still here: investors keen on health despite market shun
Experts
ScoPo’s health powerplays: Ramp ups and turnaround favs
Experts
ScoPo’s health powerplays: Cap raises goin’ crazy
Experts
This fund manager suggests investors need to look for businesses that will ‘always be there’
Health & Biotech
Check up: Is anyone making non-COVID-19 money these days? Actually, yes
News
This is what being on a ‘war footing’ against COVID-19 looks like
Health & Biotech
Dr Boreham’s Crucible: Why unlisted Qbiotics has a good chance of cracking the cancer market
Health & Biotech
Dr Boreham’s Crucible: The small cap biotechs trying to make a buck from coronavirus
Health & Biotech
Dr Boreham’s Crucible: Cochlear can weather the coronavirus-induced China slump
News
Will China’s post-virus stimulus help or hurt your stock?
Health & Biotech
Health: Oventus isn’t sleeping on the job because it’s making too much money
Health & Biotech
Health: Are Uscom’s sales *really* up on coronavirus?
News
